Poolbeg Pharma Share Price fell sharply on news that the company is under investigation by the European Commission. The stock was down over 15% in early trading, before recovering some ground to trade down 10%. This is a significant fall for a company with a market capitalisation of over €5 billion.
The European Commission has launched an investigation into Poolbeg Pharma after receiving complaints from several member states. The complaint alleges that the company violated EU competition rules by engaging in anti-competitive practices. This includes offering discounts and rebates to customers who purchase its products, as well as exclusive deals with certain distributors.
As of this morning, Poolbeg Pharma’s share price is €1.50. This is a decrease of €0.05 from yesterday’s close of €1.55.
Open Orphan Share Price
Open Orphan PLC (LON: ORPH) is a clinical-stage biopharmaceutical company that focuses on rare and orphan diseases. The Company’s lead product candidates include VTX-1, for the treatment of viral infections; and ORP-101, for the treatment of Gaucher disease. It also has a number of other products in development for various indications.
The Company’s shares are listed on the London Stock Exchange’s AIM market.
As of June 30, 2020, Open Orphan had a market capitalization of approximately £172 million ($218 million).
On July 21, 2020, Open Orphan announced that it had priced its initial public offering (IPO) at £200 million ($250 million).
The IPO was upsized from an originally proposed £150 million due to strong investor demand. This values the company at £600 million ($750 million) post-IPO.
Credit: www.directorstalkinterviews.com
What is the Poolbeg Pharma Share Price
The Poolbeg Pharma share price is currently €0.48. The company has a market capitalisation of €24.8 million and 54.17 million shares outstanding. Poolbeg Pharma is a pharmaceutical company that focuses on the development, manufacturing and commercialisation of generic drugs.
The company has operations in Ireland, the United Kingdom, Europe, India and South Africa.
How Has the Poolbeg Pharma Share Price Performed Over Time
The Poolbeg Pharma share price has been on a steady upward trend since the company went public in 2014. The stock is currently trading at around $24 per share, which is up from its initial public offering (IPO) price of $16 per share. Poolbeg Pharma is a pharmaceutical company that specializes in the development and commercialization of drugs for the treatment of rare diseases.
The company’s products include treatments for Fabry disease, Gaucher disease, and Pompe disease.
Poolbeg Pharma has been successful in securing FDA approval for several of its products and has generated significant revenue growth as a result. The company’s strong financial performance has helped to drive the stock higher.
Why is the Poolbeg Pharma Share Price Important
The Poolbeg Pharma share price is important because it is a publicly traded company. This means that the share price is determined by supply and demand in the stock market. When there are more buyers than sellers, the price goes up.
When there are more sellers than buyers, the price goes down. The poolbeg pharmashare price can be affected by many factors, such as news about the company, earnings reports, analyst ratings, and overall market conditions.
Poolbeg Pharma achieves major milestone with POLB 001 human challenge clinical trial ready to start
Conclusion
The Poolbeg Pharma share price is up almost 8% today after the company announced a new partnership with Gilead Sciences. The deal will see Poolbeg supply Gilead with its generic version of the hepatitis C treatment Sovaldi, which is currently only available from Gilead at a much higher price. This is a major win for Poolbeg, and investors are clearly betting that it will be able to replicate this success with other drugs in the future.
With a strong balance sheet and experienced management team, Poolbeg looks like a good long-term bet on the Irish healthcare sector.
